title: Targeting: the ADEPT story so far.
abstract: Antibody-directed enzyme prodrug therapy aims to restrict the action of a cytotoxic drug to cancer sites. An enzyme that has no human analogue is delivered to cancer sites by attachment to an antibody directed at a tumour associated antigen. In a second step an antibody or other agent inactivates and clears enzyme from blood. The third step is administration of a low toxicity prodrug that is a substrate for the enzyme thus generating a potent cytotoxic agent at cancer sites. Encouraging results were obtained with this system in small scale clinical trials using unrefined agents. During the past 10 years attempts have been made to reduce the system to two components. Although these have met with some success it is now accepted that future progress requires all three components.
authors.affiliation: Medical Oncology, Imperial College London, UK. kbagshawe@googlemail.com
authors.forename: K D
authors.initials: KD
authors.lastname: Bagshawe
mesh_terms: D000906:Antibodies / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D057487:Enzyme Therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D011355:Prodrugs / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
chemical_list: D000906:Antibodies; D000970:Antineoplastic Agents; D011355:Prodrugs; D011993:Recombinant Fusion Proteins